Drug Database
Back to search

United States· US:0024-5919_b44139c4-a8c5-4a25-8809-b2183a0addbd

Dupixent

A dupilumab product containing dupilumab, registered in United States by Sanofi-Aventis U.S. LLC. The same ATC class is registered in 16 of our 19 countries.

ATC D11AH05US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedDupixentATCD11AH05REGISTER NO.US:0024-5919_b44139c4…PACKS LISTED2CHECKEDJune 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about dupilumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Dupilumab is registered in 16 of 19 countries.

Countries holding a registration under ATC D11AH05 (dupilumab), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 10 of them publish a price we can compare per daily dose
Search dupilumab products by name

Dupilumab · ATC D11AH05

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of dupilumab costs, country by country.

Normalised to the WHO defined daily dose (21.4 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Dupilumab · price per daily dose (21.4 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$72.07
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
DUPILUMAB
Manufacturer
Sanofi-Aventis U.S. LLC
Country
United States (US)
ATC code
D11AH05
ATC class
Dupilumab
Defined daily dose
21.4 mg, P
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
June 26, 2026

Packs & prices · 2

  • ndc11
    0024-5919-02
  • ndc11
    0024-5919-20

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

56 interactions on record for dupilumab.

Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check dupilumab against other medicinesHow interaction checks work

Dupilumab · interactions on record

56 records

  • 27 severe
  • 22 moderate
  • 7 minor

Most severe, free to view

  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Dupilumab in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All dupilumab products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Dupixent
  • Iceland · Dupixent
  • Liechtenstein · Dupixent
  • Norway · Dupixent

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/32bfb1a4-964e-4b91-9347-5c18748d9190
GET /v1/drugs/32bfb1a4-964e-4b91-9347-5c18748d9190?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "SUBCUTANEOUS",
  "source": "ndc",
  "strength": "200",
  "substance": "DUPILUMAB",
  "productndc": "0024-5919",
  "dosage_form": "INJECTION, SOLUTION",
  "dea_schedule": null,
  "strength_unit": "mg/1.14mL",
  "application_number": "BLA761055",
  "marketing_category": "BLA"
}
API referenceMCP serverPlans

See everything about dupilumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console